Lexicon Pharmaceuticals to announce Phase 2b PROGRESS study results for diabetic neuropathic pain drug

From GlobeNewswire: 2025-03-02 16:13:22

Lexicon Pharmaceuticals, Inc. will share Phase 2b PROGRESS study results for pilavapadin (LX9211), an investigational treatment for diabetic peripheral neuropathic pain, on March 3, 2025. The study enrolled 496 adult patients with moderate to severe DPNP and evaluated different dosages of pilavapadin. DPNP affects around 9 million people in the U.S. Pilavapadin is a selective AAK1 inhibitor designed to alleviate neuropathic pain without affecting opiate pathways. Lexicon Pharmaceuticals focuses on developing innovative medicines to treat various diseases. For more information, visit their website.



Read more at GlobeNewswire: Lexicon Pharmaceuticals to Announce Topline Results from